Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Inclusion Criteria:

* male or female subjects age 18 to 80 years, inclusive, with any International Prognostic Index score; treated with 6 or more cycles of first-line CHOP chemotherapy and achieved a PR, CRu, or CR
* de novo diffuse large B-cell NHL according to the REAL classification; Ann Arbor stage III, stage IV, or bulky stage II disease (any mass ≥10 cm in diameter)
* less than an average of 25% of the intratrabecular marrow space involved by NHL in bilateral bone marrow biopsy specimens or \<10% involvement with NHL from unilateral bone marrow biopsy; tumor tissue expressing the CD20 antigen
* ≥60% performance status on the Karnofsky Performance Scale and an anticipated survival of at least 3 months
* absolute neutrophil count (ANC) ≥1500 cells/mm3 and platelet count ≥100,000/mm3
* adequate renal function (serum creatinine \<1.5 × upper limit of normal \[ULN\]) and hepatic function (total bilirubin ≤2.0 × ULN and aspartate aminotransferase \<5 × ULN)

Exclusion Criteria:

* prior radiation, prior biological therapy, or prior chemotherapy other than first-line CHOP
* active bilateral obstructive hydronephrosis
* New York Heart Association class III or IV heart disease or other serious illness
* prior malignancy other than lymphoma (except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which they had been disease-free for \>5 years)
* human immunodeficiency virus infection
* HAMA positive
* brain or leptomeningeal metastases at any time since diagnosis
* active infection requiring intravenous anti-infectives
* pregnant or breastfeeding